8 tracked superinvestors hold Eli Lilly & Co (LLY), worth $13.9B combined, led by PRIMECAP team. Smart money is accumulating LLY as of the latest 13F filings.
Current price
$1148.20
+55.0%
1Y
Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog family (e.g., Mix 75/25, U-100, U-200, Mix 50/50), insulin lispro products…
Market cap
$910.2B
P/E
34.25
Div yield
0.6%
Revenue YoY
44.7%
Analyst target
$1342
Snapshot for context. For deep analysis use a stock screener — this page is about who owns it.
Superinvestors holding
8
tracked 13F / N-PORT funds
Combined value
$13.9B
disclosed long exposure
Tier-1 conviction
1
concentrated holders
Net this quarter
+2
4 buying · 2 selling
Smart money is net accumulating LLY: 4 funds added or opened versus 2 trimming. 1 opened a brand-new position.
Eli Lilly & Co (LLY) is held by 8 tracked funds worth $13.9B combined, 1 of them concentrated Tier-1 managers whose positions carry real conviction.
The highest-conviction holder is PRIMECAP team, who has committed 6.9% of their portfolio to it.
This quarter 1 fund opened a brand-new position (Stanley Druckenmiller), with 3 adding and 2 trimming — a net accumulation signal.
| Investor | Move | % of their portfolio | Position value |
|---|---|---|---|
| Held | 6.9% | $6.5B | |
| Held | 2.3% | $3.7B | |
| Added | 2.4% | $2.2B | |
| Trimmed | 0.6% | $1.1B | |
| Trimmed | 5.6% | $119M | |
| Added | 0.4% | $104M | |
| Added | 0.6% | $93M | |
| New buy | 0.3% | $15M |
Tier badge = signal quality: 1 concentrated conviction · 2 quant/multi (context) · 3 retail & diversified. Only Tier 1 holdings feed the consensus signal.
Disclosed put/call positions — directional bets, not share ownership. A put is typically bearish or a hedge.
Calls (bullish)
None disclosed.
3 insiders filed SEC Form 144 for $730M of proposed sales in the last 90 days. A 144 is filed before the trade — see who else is selling.
| Insider | Role | Shares | Value | Filed |
|---|---|---|---|---|
| Donald Zakrowski | Officer | 2,000 | $2M | 2026-08-10 |
| Hakim Anat | Officer | 10,000 | $12M | 2026-08-07 |
| Lilly Endowment, Inc. | Shareholder | 310,000 | $372M | 2026-07-07 |
| Lilly Endowment, Inc. | Shareholder | 305,000 | $344M | 2026-06-26 |
Which superinvestors own LLY?
8 tracked funds hold Eli Lilly & Co (LLY), the largest being PRIMECAP team (Vanguard PRIMECAP) at 6.9% of its 13F portfolio. 1 of them are concentrated Tier-1 conviction managers.
Is smart money buying or selling LLY?
In the most recent 13F quarter, 4 tracked funds added or opened LLY and 2 trimmed it, including 1 brand-new position.
How much LLY do tracked funds hold?
Combined disclosed long exposure to LLY across tracked superinvestors is $13.9B as of the Jun 2026 filings.
One email when a tracked manager opens, adds to or files to sell a position — from Form 4, 13D and Form 144, not the 45-day-old 13F.
Holdings aggregated from the latest SEC 13F & N-PORT filings via FMP · Jun 2026 quarter. Long equity positions only, reported with up to a 45-day delay — for activity between filings see real-time moves. Not financial advice.